share_log

Canaccord Genuity Downgrades Galmed Pharmaceuticals to Hold, Lowers Price Target to $1

Benzinga Real-time News ·  Aug 8, 2022 06:14

Canaccord Genuity analyst Edward Nash downgrades Galmed Pharmaceuticals (NASDAQ:GLMD) from Buy to Hold and lowers the price target from $5 to $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment